The backlash over surging drug prices is starting to take hold.
Dendreon Inc. ’s $93,000 price tag for its Provenge prostate cancer treatment must be covered under the rules of the U.S. Medicare health plan, according to a letter submitted by the American Society of Clinical Oncology .
Employers in the U.S. probably added more than 200,000 jobs for a fourth straight month in May, highlighting further progress in the labor market, data in the coming week may show.
Middle-aged men who stayed fit were less likely to die from three common cancers after being diagnosed than those who were out of shape, research found.
Abraxis BioScience Inc. ’s drug Abraxane benefitted more than one-third of pancreatic-cancer patients who didn’t respond to a standard treatment, a study found.
Pinpointing the genetic changes that cause cancer has been a focus of researchers for more than a decade. Now, top cancer hospitals are making genetic testing a new standard of care in the field.